IMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Immuneering Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$3.66+0.07 (+1.95%)
Close on Oct 19, 2026
- Market cap
- $236.79M
- P/E (TTM)
- –
- Dividend yield
- –
Community
Notes and questions about Immuneering from other investors
No posts about IMRX yet
Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.